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Abstract. Tyr-3-Octreotide is a synthetic derivative of 
somatostatin a d a somatostatin-receptor analogue. The 
iodine-123-1abelled compound localizes omatostatin-re- 
ceptor-positive tumours. In this paper two patients are 
reported in whom somatostatin receptors were demon- 
strated in vitro. In a 60-year-old female with an islet 
cell carcinoma of the pancreas, multiple liver metastases 
and previously unrecognized bone metastases in the 
right acetabulum could be diagnosed as the reason for 
a persistent hypoglycaemia. In a 60-year-old male an 
islet cell carcinoma of the pancreas was localized with 
lz3I-Tyr-3-octreotide. The somatostatin receptors were 
demonstrated in vitro and the turnout was successfully 
treated with somatostatin. These studies demonstrate 
that lz3I-Tyr-3-octreotide offers the possibility of loca- 
lizing somatostatin-receptor-positive tumours and their 
metastases. Moreover the method makes it possible to 
determine the receptor status of a tumour in vivo. 
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Introduction 
Iodine 123 tyr-3-octreotide 201-995, a synthetic deriva- 
tive of somatostatin, is a somatostatin receptor analogue 
(Bakker et al. 1990) which has been introduced for the 
localization of somatostatin receptor-positive tumours 
(Krenning et al. 1989; Lamberts et al. 1990a, b, c). A 
parallel between the evidence of somatostatin receptors 
on tumours and in vivo and in vitro effects of octreotide 
on hormonal release from these tumours indicates that 
a positive scan predicts a good suppressive effect of oc- 
treotide on hormonal hypersecretion by these endocrine 
tumours. This is one of the possible future indications 
for an iodine 123 tyr-3-octreotide scan. Another indica- 
tion is based on the fact that, with the exception of 
insulinomas, most endocrine pancreatic tumours are 
malignant and have already metastasized at the time 
of diagnosis (Bloom and Polak 1980; Stefani et al. 1974), 
so surgery is considered to be the primary treatment. 
For this reason, a specific and sensitive method for the 
localization of all tumour manifestations is required. 
This case report confirms the positive result of pre- 
vious papers dealing with iodine 123 tyr-3-octreotide 
(Krenning et al. 1989; Lamberts et al. 1990a, b, c). Non- 
tumour elated uptake is also described. 
Materials and patients 
Radiopharmaceuticals. The radiolabelling of tyr-3-octreotide was 
performed according to a previously published method (Bakker 
et al. 1990). Tyr-3-octreotide was obtained from Sandoz (Basel, 
Switzerland). The radioiodination of the tracer was performed with 
~23I from Medgenix, Belgium. The radioactivity concentration and 
specific activities amounted to 3.7 GBq/ml. Normal patient activity 
was 185 MBq iodine 123 tyr-3-octreotide. There were no side effects 
recorded. All patients gave their written informed consent for this 
examination. 
Data acquisition. Gamma-camera images were performed as planar 
(128 x 128 matrix) and SPET images (64 x 64 matrix) with a Sie- 
mens Rota gamma-camera fitted with a low-energy, high-resolu- 
tion collimator. Data were collected with a Siemens Microdelta 
computer. The image time was routinely 5-45 min post injection 
(p.i.) and 2-3 h p.i. The relevant images were performed uring 
the first 30 rain, before the beginning of the intestinal excretion 
of the 12aI-labelled metabolites of tyr-3-octreotide. The SPET im- 
age of the liver was performed 2 h p.i. after significant clearance 
of the iodine by the liver. 
In vitro determination of somatostatin receptors. Somatostatin re- 
ceptors were measured by autoradiography on cryostat sections 
of the turnout tissues as described previously in detail for various 
endocrine tumours (Reubi et al. 1987, 1990). 
Case reports 
Patient 1. A 60-year-old man who suffered from a weight loss 
of 10 kg and heavy diarrhoea during the past 2 months was admit- 
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Fig. 1. A 60-year-old man with somatostatin receptor-positive, 
non-resectable pancreatic islet carcinoma, which is specifically 
shown with iodine 123 tyr-3-octreotide b tween the activity of both 
kidneys in a planar abdominal scan 
ted to our hospital (April 1984). Ultrasound, computed X-ray to- 
mography and magnetic resonance imaging localised a pancreatic 
mass of 9 x 6 cm diameter with compression of the vena cava and 
aorta without any signs of infiltration but with occlusion of the 
vena lienalis and the vena mesenterica superior. The tumour of 
the pancreas produced no clinically detectable product and was 
judged to be inactive. 
During explorative surgery the tumour proved not to be resect- 
able (May 1984). Biopsy specimen of the tumour evealed an islet 
cell carcinoma. At that time the autoradiography of somatostatin 
receptors was not yet possible, and Sandostatin was not available. 
The patient underwent 21 courses of fluorouracil and streptozocin 
treatment over the subsequent 3 years. The tumour size did not 
change, but the symptoms, especially weakness and faintness, in- 
creased. At this time (Nov. 1987) an ultrasound-guided biopsy of 
the pancreatic turnout was examined with autoradiography, which 
demonstrated a significant number of somatostatin receptors ex- 
pressed on the turnout issue. Following this diagnosis treatment 
with 3 x 500 jig of Sandostatin given subcutaneously was started. 
From this time on, the patient recovered quickly, and the tumour 
size decreased slightly. In Aug. 1990 an iodine 123 tyr-3-octreotide 
scan was performed after a 3-day interruption of the Sandostatin 
treatment. The scan (Fig. 1) demonstrated a large tumour mass 
between both kidneys and under the liver with significant tracer 
uptake. Other manifestations of the tumour could not be detected. 
Patient 2. A 60-year-old woman was admitted to our hospital (April 
1988) with hypoglycaemia, weight loss of 20 kg and pain attacks 
in the upper abdomen. The reason for the hypoglycaemic attacks 
was a pancreatic tumour with already widespread liver metastases. 
The tumour proved to be active. Insulin levels (104 #E/ml; normal 
1-20 gE/ml), C-peptide concentration (69 ng/ml; normal 0.6-5.4 
ng/ml), serum glucose levels (150-250 rag/100 ml) and growth hor- 
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mone levels (85.9 ng/ml; normal < 1 ng/ml) were elevated. In the 
same month the pancreatic tail with an islet cell carcinoma and 
the left liver lobe were resected, emonstrating widespread metas- 
tases in the liver. After 8 cycles of a 5-fluorouracil and streptozocin 
treatment, computed tomography scans demonstrated a small de- 
crease in the size of the liver metastases. In March 1990 an ultra- 
sound-guided liver biopsy, examined in the laboratory of Dr. Reubi 
demonstrated in more than 10% of all tumor cells highly positive 
somatostatin receptors. A Sandostatin treatment was started with 
3 x 100 gg subcutaneously per day. In April 1990 an iodine 123 
tyr-3-octretide scan was performed, which demonstrated only a 
faint, patchy, increased uptake in the liver (Fig. 2a), which could 
only be interpreted as positive after knowledge of the sonographic 
and computed tomographic results. The scan revealed a significant 
pathological uptake in the right acetabulum (Fig. 2b), which was 
suspected to be metastatic. X-radiographs demonstrated anosteo- 
lytic process in this region. The symptoms of hygolycaemia and 
the patient's general condition seriously worsened, and the patient 
started to complain of right-sided hip pain. In June 1990 a percuta- 
neous radiation treatment of the right hip with 10 MV photons 
was started, up to a total dose of 36 Gy. A subsequent total hip 
replacement (Aug. 1990) only demonstrated osteonecrosis from the 
radiation therapy and no tumonr tissue. Despite continuing soma- 
tostatin treatment and a permanent glucose infusion, the patient 
died in Jan. 1991. 
Discussion 
Previous papers (B loom and Polak 1980; Stefani et al. 
1974) have already demonstrated that, with the excep- 
t ion of  insul inomas, most  endocr ine pancreat ic  tumours  
are mal ignant  and have metastasized at the time of  diag- 
nosis. Case report  1 describes one of  these rare, inf i l trat- 
ing, unresectable, endocrine- inact ive islet cell tumours  
at the time of  diagnosis.  Moreover ,  this case demon-  
strates very well the f inding of  earl ier reports (Lamberts  
et al. 1990a, b, c) that  the results of  gamma-camera  
scans after injection of  iodine 123 tyr-3-octreotide,  a 
cheap and harmless technique, have a close relat ionship 
with the in vitro detect ion of  somatostat in  receptors in 
the tumours  using autorad iography.  This indicates, 
therefore, that  the l igands binding to the tumour  in vivo 
indeed represent b inding to specific somatostat in  recep- 
tors. The fact is proven in case report  1 by the therapeu- 
tic effectiveness of  octreot ide via growth inhibit ion of  
this tumour  over years. This points out the high specifici- 
ty o f  this new technique of  tumor  imaging. Furthermore,  
this technique provides increased iagnost ic  accuracy in 
the presurgical  local isat ion of  insul inomas, which ranges 
at the moment ,  dependent on the method used and the 
local isat ion of  the tumour,  between 14% and 100% 
(Junginger et al. 1990). 
Because there is a wide var iat ion in the clinical pre- 
sentat ion of  endocr ine pancreat ic  tumours  in man,  there 
are tumours  which present with signs and symptoms 
related to the hormona l  hypersecret ion f rom these tu- 
mours,  others with symptoms related to the tumour  
mass itself. In these latter cases, as demonstrated in case 
report  1, these often undif ferent iated tumours  do not  
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Fig. 2a. The iodine 123 tyr-3-octreotide planar scan demonstrates 
significant pathological uptake in th  r ght acetabulum, where x- 
radiographs later demonstrated an osteolytic tumour (anterior 
view), b A 60-year-old woman with metastatic somatostatin recep- 
tor-positive pancreatic islet cell carcinoma. The iodine 123 tyr-3- 
octreotide single photon emission tomogram of the liver demon- 
strates a patchy, increased uptake in the metastases 
secrete considerable amounts of biologically active hor- 
mones, or the clinical picture is rather inconspicious 
(Lamberts et al. 1990b; Stefani et al. 1974). Here the 
iodine 123 tyr-3-octreotide scan might be helpful in dem- 
onstrating somatostatin receptors on pancreatic tu- 
mours, which helps in the differential diagnosis of ductal 
adenocarcinomas, which have no somatostatin receptors 
from endocrine pancreatic arcinomas (Lamberts et al. 
1990c). Therefore, this method might be a safe alterna- 
tive to in vivo octreotide application in the selection 
of insulinoma patients for chronic treatment with the 
drug, which has been previously proposed. 
In the second patient, somatostatin receptors were 
shown earlier on the primary tumour. This was the indi- 
cation for the somatostatin scan, because such specific 
receptors could be expected in the metastases also. For 
this reason, the known liver metastases could be detected 
as small areas of increased uptake in the liver, which 
were the reason for the increased insulin secretion in 
this patient. The scan demonstrated another more strik- 
ing lesion in the right hip, which was found to be another 
metastasis from the insulinoma. 
The benefit of the scan can be easily demonstrated 
in case report 2, as besides the already known liver me- 
tastases another large focus was detected in the right 
hip before clinical symptoms appeared, leading to surgi- 
cal treatment. However, due to the liver metastases the 
hyperinsulinaemia persisted even under continuing oc- 
treotide medication. 
In conclusion, we have confirmed in this study the 
results of iodine 123 tyr-3-octreotide scans from other 
groups (Lamberts et al. 1990a). This method opens for 
the first time up the possibility of the localization of 
somatostatin receptor-positive tumours and their metas- 
tases. Second, this method offers a non-invasive proce- 
dure to determine tumour eceptor status. Theoretically, 
this new approach of scintigraphic tumour detection 
might be extended to other receptor-containing tumours 
and by this way may offer an alternative to immunoscin- 
tigraphy with monoclonal ntibodies. 
Acknowledgements. We gratefully thank Dr. J. Pless (Pharma Divi- 
sion, Sandoz AG, Basel, Switzerland) for the support with tyr-3- 
octreotide and Dr. J.C. Reubi (Sandoz Research Institute, Bern 
Switzerland) for demonstrating the somatostatin receptors in the 
tumour tissue. 
References 
Bakker WH, Krenning EP, Breeman WA, Koper JW, Kooij PP, 
Reubi JC, Klijn JG, Visser TJ, Docter R, Lamberts SW (1990) 
Receptor scintigraphy with a radioiodinated somatostatin a a- 
927 
logue: radiolabeling, purification, biologic activity and in vivo 
application i animals. J Nucl Med 31 : 1501-1509 
Bloom SR, Polak JM (1980) Glucagonomas, VIPomas and soma- 
tostatomas. Clin Endocrinol Metab 9:285-297 
Junginger T, B6ttger T, Beyer J, Thelen M (1990) Der organische 
Hyperinsulinismus-Diagnostik und Therapie. Dtsch Artzebl 
87:B2418-B2423 
Krenning EP, Bakker WH, Breeman WAP, Koper JW, Kooij PPM, 
Ausema L, Lameris JS, Reubi JC, Lamberts SWJ (1989) Local- 
ization of endocrine-related umours with radioiodinated ana- 
logue of somatostatin. Lancet I : 242-244 
Lamberts SWJ, Bakker WH, Reubi JC, Krenning EP (1990a) 
Treatment with sandostatin and in vivo localization of tumors 
with radiolabeled somatostatin a alogs. Metabolism 39:152- 
155 
Lamberts SWJ, Bakker WH, Reubi JC, Krenning EP (1990b) So- 
matostatin-receptor imaging in the localization of endocrine 
tumors. N Engl J Med 323:1246-1249 
Lamberts SWJ, Hofland LJ, Koetsfled van PM, Reubi JC, Bruining 
HA, Bakker WH, Krenning EP (1990c) Parallel in vivo and 
in vitro detection of functional somatostatin receptors in human 
endocrine pancreatic tumours: consequences with regard to di- 
agnosis, localization and therapy. J Clin Endocrinol Metab 
71 : 566-574 
Reubi J-C, Hacki WH, Lamberts SWJ (1987) Hormone producing 
gastrointestinal tumors contain a high density of somatostatin 
receptors. J Clin Endocrinol Metab 65:1127-1134 
Reubi JC, Kvols L, Krenning E, Lamberts SWJ (1990) Distribution 
of somatostatin receptors in normal and tumor tissue. Metabo- 
lism 39 : 78-81 
Stefani P, Carboni M, Patrassi N, Basoli A (1974) Beta-islet tumors 
of the pancreas: results on 1067 cases. Surgery 75:597-609 
